Investment
Advanced Therapies for liver diseases
Starting a Serie A to develop a drug for NASH to start the preclinical development phase
Author
CEO
Servatrix
Madrid, Spain
Spin off of the UAM. Startup focus on developing new molecules to treatment of NASH/MASH and autoinmune diseases
Skills
Interests
Additional questions
Areas od activity
Organization type
SMEInvestment
Advanced Therapies for liver diseases
Starting a Serie A to develop a drug for NASH to start the preclinical development phase